Cargando…
BIK drives an aggressive breast cancer phenotype through sublethal apoptosis and predicts poor prognosis of ER-positive breast cancer
Apoptosis is fundamental to normal animal development and is the target for many anticancer therapies. Recent studies have explored the consequences of “failed apoptosis” where the apoptotic program is initiated but does not go to completion and does not cause cell death. Nevertheless, this failed a...
Autores principales: | Pandya, Vrajesh, Githaka, John Maringa, Patel, Namrata, Veldhoen, Richard, Hugh, Judith, Damaraju, Sambasivarao, McMullen, Todd, Mackey, John, Goping, Ing Swie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289861/ https://www.ncbi.nlm.nih.gov/pubmed/32528057 http://dx.doi.org/10.1038/s41419-020-2654-2 |
Ejemplares similares
-
The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer
por: Pandya, Vrajesh, et al.
Publicado: (2016) -
Non-canonical BAD activity regulates breast cancer cell and tumor growth via 14-3-3 binding and mitochondrial metabolism
por: Mann, Jasdeep, et al.
Publicado: (2019) -
BAD regulates mammary gland morphogenesis by 4E-BP1-mediated control of localized translation in mouse and human models
por: Githaka, John Maringa, et al.
Publicado: (2021) -
BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis
por: Mann, Jasdeep, et al.
Publicado: (2020) -
Lysophosphatidate Induces Chemo-Resistance by Releasing Breast Cancer Cells from Taxol-Induced Mitotic Arrest
por: Samadi, Nasser, et al.
Publicado: (2011)